Abstract
The clinical implications of COVID-19 in pregnancy remain unknown. While preliminary reports demonstrate that pregnant patients have a similar symptomatic presentation to the general population, the appropriate management and timing of delivery in these patients is still unclear, as pregnancy may impose additional risk factors and impede recovery in gravid patients. In this brief report, we present a case of COVID-19 in a pregnant patient with severe respiratory compromise, whose clinical status significantly improved after caesarean delivery. We also address the potential benefits of experimental therapy, including tocilizumab, a monoclonal antibody that targets interleukin-6 receptors.
Original language | English |
---|---|
Article number | e236290 |
Journal | BMJ Case Reports |
Volume | 13 |
Issue number | 7 |
DOIs | |
State | Published - 16 Jul 2020 |
Keywords
- immunological products and vaccines
- infectious diseases
- obstetrics and gynaecology